董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stephen W. Webster | 男 | Director | 55 | 15.44万美元 | 未持股 | 2017-02-28 |
| J. Matthew Singleton | 男 | Director | 64 | 15.33万美元 | 未持股 | 2017-02-28 |
| Matthew W. Foehr | 男 | Director | 44 | 13.77万美元 | 未持股 | 2017-02-28 |
| Lawson Macartney | 男 | Chairperson of the Board of Directors | 59 | 17.17万美元 | 未持股 | 2017-02-28 |
| Brian Lian | 男 | President and Chief Executive Officer, Director | 51 | 218.54万美元 | 未持股 | 2017-02-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Morneau | 男 | Chief Financial Officer | 51 | 175.18万美元 | 未持股 | 2017-02-28 |
| Brian Lian | 男 | President and Chief Executive Officer, Director | 51 | 218.54万美元 | 未持股 | 2017-02-28 |
董事简历
中英对照 | 中文 | 英文- Stephen W. Webster
-
Stephen W. Webster 于 2020 年 5 月加入 Tcr2 Therapeutics Inc. 董事会，并于 2022 年 1 月成为 Tcr2 Therapeutics Inc. 董事长。Webster 先生自 7 月起担任上市基因治疗生物技术公司 Spark Therapeutics 的首席财务官2014 年至 2019 年 12 月被罗氏以 48 亿美元收购。从 2012 年 7 月至 2013 年 10 月被 Cubist Pharmaceuticals 收购，他曾担任上市生物技术公司 Optimer Pharmaceuticals 的高级副总裁兼首席财务官。加入 Optimer 后，Webster 先生从 2008 年到 2011 年被 Cubist Pharmaceuticals 收购，担任生物制药公司 Adolor Corporation 的高级副总裁兼首席财务官。Webster 先生还曾在 Broadpoint Capital 的投资银行医疗保健集团和PaineWebber 公司。 Webster 先生自 2019 年 4 月起担任 NextCure 的董事，自 2016 年 8 月起担任 Nabriva Therapeutics AG（前身为 Nabriva Therapeutics plc），自 2020 年起担任 Cullinan Oncology, Inc. 的董事。Webster 先生获得了 A.B.达特茅斯学院经济学学士学位和宾夕法尼亚大学沃顿商学院金融学工商管理硕士学位。
Stephen W. Webster joined Tcr2 Therapeutics Inc. Board of Directors in May 2020 and became Tcr2 Therapeutics Inc. Chairman in January of 2022. Mr. Webster served as the Chief Financial Officer of Spark Therapeutics, a publicly traded gene therapy biotechnology company, from July 2014 until its acquisition by Roche for $ 4.8 billion in December 2019. He was previously Senior Vice President SVP and Chief Financial Officer of Optimer Pharmaceuticals, a publicly traded biotechnology company, from July 2012 until its acquisition by Cubist Pharmaceuticals in October 2013. Prior to joining Optimer, Mr. Webster served as SVP and Chief Financial Officer of Adolor Corporation, a biopharmaceutical company, from 2008 until its acquisition by Cubist Pharmaceuticals in 2011. Mr. Webster also served in leadership positions in the investment banking healthcare groups of Broadpoint Capital and PaineWebber Incorporated. Mr. Webster has served as a director of NextCure since April 2019 Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc) since August 2016 and Cullinan Oncology, Inc. since 2020. Mr. Webster received an A.B. in Economics from Dartmouth College and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania. - Stephen W. Webster 于 2020 年 5 月加入 Tcr2 Therapeutics Inc. 董事会，并于 2022 年 1 月成为 Tcr2 Therapeutics Inc. 董事长。Webster 先生自 7 月起担任上市基因治疗生物技术公司 Spark Therapeutics 的首席财务官2014 年至 2019 年 12 月被罗氏以 48 亿美元收购。从 2012 年 7 月至 2013 年 10 月被 Cubist Pharmaceuticals 收购，他曾担任上市生物技术公司 Optimer Pharmaceuticals 的高级副总裁兼首席财务官。加入 Optimer 后，Webster 先生从 2008 年到 2011 年被 Cubist Pharmaceuticals 收购，担任生物制药公司 Adolor Corporation 的高级副总裁兼首席财务官。Webster 先生还曾在 Broadpoint Capital 的投资银行医疗保健集团和PaineWebber 公司。 Webster 先生自 2019 年 4 月起担任 NextCure 的董事，自 2016 年 8 月起担任 Nabriva Therapeutics AG（前身为 Nabriva Therapeutics plc），自 2020 年起担任 Cullinan Oncology, Inc. 的董事。Webster 先生获得了 A.B.达特茅斯学院经济学学士学位和宾夕法尼亚大学沃顿商学院金融学工商管理硕士学位。
- Stephen W. Webster joined Tcr2 Therapeutics Inc. Board of Directors in May 2020 and became Tcr2 Therapeutics Inc. Chairman in January of 2022. Mr. Webster served as the Chief Financial Officer of Spark Therapeutics, a publicly traded gene therapy biotechnology company, from July 2014 until its acquisition by Roche for $ 4.8 billion in December 2019. He was previously Senior Vice President SVP and Chief Financial Officer of Optimer Pharmaceuticals, a publicly traded biotechnology company, from July 2012 until its acquisition by Cubist Pharmaceuticals in October 2013. Prior to joining Optimer, Mr. Webster served as SVP and Chief Financial Officer of Adolor Corporation, a biopharmaceutical company, from 2008 until its acquisition by Cubist Pharmaceuticals in 2011. Mr. Webster also served in leadership positions in the investment banking healthcare groups of Broadpoint Capital and PaineWebber Incorporated. Mr. Webster has served as a director of NextCure since April 2019 Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc) since August 2016 and Cullinan Oncology, Inc. since 2020. Mr. Webster received an A.B. in Economics from Dartmouth College and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania.
- J. Matthew Singleton
-
J. Matthew Singleton，2003年6月开始，他是我们的董事会一员。2011年10月，他从CitationAir公司，以前的CitationShares有限责任公司，（一家私人飞机服务公司和赛斯纳飞机公司）的全资子公司的执行副总裁和首席财务官。赛纳斯飞机公司归德事隆，（一家上市的工业企业）所有。2000开始他担任这个职位。在过去5年，他是所罗门投资公司，（一家私人投资服务公司）的董事。
J. Matthew Singleton has served as a member of our Board since May 2014. In October 2011 Mr. Singleton retired from his position as Executive Vice President and Chief Financial Officer of CitationAir formerly CitationShares LLC, a privately held jet services company wholly-owned by Textron Inc., a public industrial conglomerate. He had served in this position since 2000. Mr. Singleton has extensive financial, accounting and transactional experience, including through his role as Managing Director, Executive Vice President and Chief Administrative Officer of CIBC World Markets, an investment banking company, for 20 years, from 1974 to 1994 at Arthur Andersen & Co., a public accounting firm, including as Partner-in-Charge of the Metro New York Audit and Business Advisory Practice, and as a Practice Fellow at the Financial Accounting Standards Board, a private organization responsible for establishing financial accounting reporting standards. From 2003 until 2014 Mr. Singleton served as a director of Cubist Pharmaceuticals Inc., and as Audit Committee Chair beginning in 2004. Mr. Singleton previously served as an independent director of Salomon Reinvestment Company Inc., a privately held investment services company. Mr. Singleton received an AB in Economics from Princeton University and his MBA from New York University with a focus in Accounting. - J. Matthew Singleton，2003年6月开始，他是我们的董事会一员。2011年10月，他从CitationAir公司，以前的CitationShares有限责任公司，（一家私人飞机服务公司和赛斯纳飞机公司）的全资子公司的执行副总裁和首席财务官。赛纳斯飞机公司归德事隆，（一家上市的工业企业）所有。2000开始他担任这个职位。在过去5年，他是所罗门投资公司，（一家私人投资服务公司）的董事。
- J. Matthew Singleton has served as a member of our Board since May 2014. In October 2011 Mr. Singleton retired from his position as Executive Vice President and Chief Financial Officer of CitationAir formerly CitationShares LLC, a privately held jet services company wholly-owned by Textron Inc., a public industrial conglomerate. He had served in this position since 2000. Mr. Singleton has extensive financial, accounting and transactional experience, including through his role as Managing Director, Executive Vice President and Chief Administrative Officer of CIBC World Markets, an investment banking company, for 20 years, from 1974 to 1994 at Arthur Andersen & Co., a public accounting firm, including as Partner-in-Charge of the Metro New York Audit and Business Advisory Practice, and as a Practice Fellow at the Financial Accounting Standards Board, a private organization responsible for establishing financial accounting reporting standards. From 2003 until 2014 Mr. Singleton served as a director of Cubist Pharmaceuticals Inc., and as Audit Committee Chair beginning in 2004. Mr. Singleton previously served as an independent director of Salomon Reinvestment Company Inc., a privately held investment services company. Mr. Singleton received an AB in Economics from Princeton University and his MBA from New York University with a focus in Accounting.
- Matthew W. Foehr
-
Matthew W. Foehr， 自2011年起担任执行副总裁和首席运营官；他在管理全球研究和开发项目上有超过19年的工作经验。2011年加入Ligand之前，他是 Consumer Dermatology R&D副总裁和主管以及GlaxoSmithKline GSK。公司Stiefel 分部 Dermatology的代理首席技术官。2009年GSK以36亿买下Stiefel之后，他负责领导Stiefel和GSK的研发整合。在Stiefel Laboratories, Inc.，他曾担任全球研发运营高级副总裁；产品开发和支持高级副总裁；以及全球供应链技术服务副总裁。加入Stiefel之前，他在 Connetics Corporation担任多个高管职位， 包括技术运营高级副总裁和制造副总裁。他是多本科学出版物的作者，并申请了多项美国专利。他持有圣克拉拉大学生物理学学士学位。
Matthew W. Foehr,is President and Chief Executive Officer and a member of Omniab, Inc. board of directors, and has more than 25 years of pharmaceutical industry experience managing operations, technology development and global research and development programs. Mr. Foehr previously served as President and Chief Operating Officer at Ligand Pharmaceuticals from 2015 to 2022 and prior to that, served as Ligand's Executive Vice President and Chief Operating Officer since 2011. Prior to joining Ligand, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline. Following GSK's acquisition of Stiefel in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. Mr. Foehr serves on the Board of Directors of Viking Therapeutics, Inc., a publicly-traded biotechnology company and served as a director of Ritter Pharmaceuticals, Inc. from 2015 until its merger with Qualigen Therapeutics, Inc. in 2020.Mr. Foehr received his BS degree in biology from Santa Clara University. - Matthew W. Foehr， 自2011年起担任执行副总裁和首席运营官；他在管理全球研究和开发项目上有超过19年的工作经验。2011年加入Ligand之前，他是 Consumer Dermatology R&D副总裁和主管以及GlaxoSmithKline GSK。公司Stiefel 分部 Dermatology的代理首席技术官。2009年GSK以36亿买下Stiefel之后，他负责领导Stiefel和GSK的研发整合。在Stiefel Laboratories, Inc.，他曾担任全球研发运营高级副总裁；产品开发和支持高级副总裁；以及全球供应链技术服务副总裁。加入Stiefel之前，他在 Connetics Corporation担任多个高管职位， 包括技术运营高级副总裁和制造副总裁。他是多本科学出版物的作者，并申请了多项美国专利。他持有圣克拉拉大学生物理学学士学位。
- Matthew W. Foehr,is President and Chief Executive Officer and a member of Omniab, Inc. board of directors, and has more than 25 years of pharmaceutical industry experience managing operations, technology development and global research and development programs. Mr. Foehr previously served as President and Chief Operating Officer at Ligand Pharmaceuticals from 2015 to 2022 and prior to that, served as Ligand's Executive Vice President and Chief Operating Officer since 2011. Prior to joining Ligand, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline. Following GSK's acquisition of Stiefel in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. Mr. Foehr serves on the Board of Directors of Viking Therapeutics, Inc., a publicly-traded biotechnology company and served as a director of Ritter Pharmaceuticals, Inc. from 2015 until its merger with Qualigen Therapeutics, Inc. in 2020.Mr. Foehr received his BS degree in biology from Santa Clara University.
- Lawson Macartney
-
Lawson Macartney，2013年2月以来，担任我们的总裁兼首席执行官以及董事会的成员。在加入我们之前，从2011年到2013年，他在夏尔AG）专业生物制药公司担任新兴业务部门的高级副总裁，他负责通过第三阶段发展计划来实现Shire的专业制药投资组合。加入夏尔公司之前，他从1999年到2011年，他任职于葛兰素史克制药公司；从2007年到2011年，他担任全球产品策略和项目/项目组合管理的高级副总裁为高级副总裁；从2004年到2007年，他担任心血管和代谢医学发展中心的副总裁；从1999年到2004年，他担任全球心血管代谢和泌尿外科治疗领域的副总裁。加入GSK之前，从1998年到1999年，他在阿斯特拉制药公司担任操作、市场营销和销售负责人；从1996年到1998年，他在AstraMerck制药公司担任商业运作执行董事。目前，他担任Viking Therapeutics公司的董事会成员。1982年，他在苏格兰格拉斯哥大学获得了博士学位，他是皇家学会研究员。1979年，他毕业于格拉斯哥大学兽医学院，他的B.V.M.S。和D.V.M。相互匹配。他接受诊断病理学的训练，是皇家学院的一位病理学家。
Lawson Macartney has served as the Chairperson of the Board since May 2015 and as a member of our Board since May 2014. Most recently, Dr. Macartney has taken the role of CEO of Scout Bio Inc., a gene therapy company developing therapies for companion animals. He has also recently been appointed to the Board of Dechra PLC, an international animal health pharmaceutical company based in the UK, and to the Supervisory Board of Netherlands Translational Research Centre, a preclinical biopharmaceutical company based in The Netherlands. Dr. Macartney served as President, Chief Executive Officer and a member of the board of directors of Ambrx Inc., a biopharmaceutical company, from February 2013 to June 2015. Prior to Ambrx, Dr. Macartney served at Shire AG, a specialty biopharmaceutical company, as Senior Vice President of the Emerging Business Unit from 2011 to 2013 where he was responsible for discovery initiatives through Phase 3 development of Shire’s Specialty Pharmaceutical portfolio. Prior to joining Shire AG, he served at GSK, a pharmaceutical company, from 1999 to 2011 serving as Senior Vice President of Global Product Strategy and Project/Portfolio Management from 2007 to 2011 as Senior Vice President, Cardiovascular and Metabolic Medicine Development Center from 2004 to 2007 and as Vice President, Global Head of Cardiovascular, Metabolic and Urology Therapeutic Areas from 1999 to 2004. Prior to joining GSK, Dr. Macartney was employed at Astra Pharmaceuticals from 1998 to 1999 in leadership roles in operations, marketing and sales, and served as Executive Director, Commercial Operations at AstraMerck, Inc., a pharmaceutical company, from 1996 to 1998. Dr. Macartney received his Ph.D. from Glasgow University in Scotland in 1982 where he was a Royal Society Research Fellow, and his B.V.M.S. equivalent to a D.V.M. in 1979 from Glasgow University Veterinary School. He is also trained in diagnostic pathology and is a Fellow of the Royal College of Pathologists. - Lawson Macartney，2013年2月以来，担任我们的总裁兼首席执行官以及董事会的成员。在加入我们之前，从2011年到2013年，他在夏尔AG）专业生物制药公司担任新兴业务部门的高级副总裁，他负责通过第三阶段发展计划来实现Shire的专业制药投资组合。加入夏尔公司之前，他从1999年到2011年，他任职于葛兰素史克制药公司；从2007年到2011年，他担任全球产品策略和项目/项目组合管理的高级副总裁为高级副总裁；从2004年到2007年，他担任心血管和代谢医学发展中心的副总裁；从1999年到2004年，他担任全球心血管代谢和泌尿外科治疗领域的副总裁。加入GSK之前，从1998年到1999年，他在阿斯特拉制药公司担任操作、市场营销和销售负责人；从1996年到1998年，他在AstraMerck制药公司担任商业运作执行董事。目前，他担任Viking Therapeutics公司的董事会成员。1982年，他在苏格兰格拉斯哥大学获得了博士学位，他是皇家学会研究员。1979年，他毕业于格拉斯哥大学兽医学院，他的B.V.M.S。和D.V.M。相互匹配。他接受诊断病理学的训练，是皇家学院的一位病理学家。
- Lawson Macartney has served as the Chairperson of the Board since May 2015 and as a member of our Board since May 2014. Most recently, Dr. Macartney has taken the role of CEO of Scout Bio Inc., a gene therapy company developing therapies for companion animals. He has also recently been appointed to the Board of Dechra PLC, an international animal health pharmaceutical company based in the UK, and to the Supervisory Board of Netherlands Translational Research Centre, a preclinical biopharmaceutical company based in The Netherlands. Dr. Macartney served as President, Chief Executive Officer and a member of the board of directors of Ambrx Inc., a biopharmaceutical company, from February 2013 to June 2015. Prior to Ambrx, Dr. Macartney served at Shire AG, a specialty biopharmaceutical company, as Senior Vice President of the Emerging Business Unit from 2011 to 2013 where he was responsible for discovery initiatives through Phase 3 development of Shire’s Specialty Pharmaceutical portfolio. Prior to joining Shire AG, he served at GSK, a pharmaceutical company, from 1999 to 2011 serving as Senior Vice President of Global Product Strategy and Project/Portfolio Management from 2007 to 2011 as Senior Vice President, Cardiovascular and Metabolic Medicine Development Center from 2004 to 2007 and as Vice President, Global Head of Cardiovascular, Metabolic and Urology Therapeutic Areas from 1999 to 2004. Prior to joining GSK, Dr. Macartney was employed at Astra Pharmaceuticals from 1998 to 1999 in leadership roles in operations, marketing and sales, and served as Executive Director, Commercial Operations at AstraMerck, Inc., a pharmaceutical company, from 1996 to 1998. Dr. Macartney received his Ph.D. from Glasgow University in Scotland in 1982 where he was a Royal Society Research Fellow, and his B.V.M.S. equivalent to a D.V.M. in 1979 from Glasgow University Veterinary School. He is also trained in diagnostic pathology and is a Fellow of the Royal College of Pathologists.
- Brian Lian
-
Brian Lian自2019年1月起担任董事。他是我们薪酬委员会的主席，我们审计委员会的成员和我们公司治理/提名委员会的成员。他目前是VikingTherapeutics，Inc.的总裁兼首席执行官和董事。Nasdaq:VKTX，生物制药公司，加入Viking之前，2012-2013，他是投资银行SunTrust Robinson Humphrey的董事总经理、高级研究分析师。在SunTrust Robinson Humphrey，他负责小型和中型生物技术公司的覆盖，重点是糖尿病、肿瘤学、传染病和神经学领域的公司。任职SunTrust Robinson Humphrey公司之前，他曾担任Global Hunter Securities公司（投资银行）的董事总经理兼高级研究分析师（2011年至2012年）。任职Global Hunter Securities公司之前，他曾担任Agave Group，LLC（注册投资顾问）的高级梦百合分析师（2008年至2011年）。任职Agave Group公司之前，他曾担任CIBC World Markets公司（投资银行）的执行董事兼高级生物技术分析师（2006年至2008年）。任职CIBC公司之前，他曾担任Amgen公司（生物技术公司）的小分子药物发现研究科学家。任职Amgen公司之前，他曾担任Microcide Pharmaceuticals公司（生物技术公司）的研究科学家。Lian博士拥有印第安纳大学（Indiana University）的会计和金融工商管理硕士学位，密歇根大学（University of Michigan）的有机化学硕士和博士学位，以及惠特曼学院（Whitman College）的化学学士学位。
Brian Lian has been a director since January 2019. He is the Chair of our Compensation Committee, a member of our Audit Committee and a member of our Corporate Governance/Nominating Committee. He is currently President and Chief Executive Officer and a Director of Viking Therapeutics, Inc. Nasdaq: VKTX, a biopharmaceutical company.Prior to joining Viking, he was a Managing Director and Senior Research Analyst at SunTrust Robinson Humphrey, an investment bank, from 2012 to 2013. At SunTrust Robinson Humphrey, he was responsible for coverage of small and mid-cap biotechnology companies with an emphasis on companies in the diabetes, oncology, infectious disease and neurology spaces. Prior to SunTrust Robinson Humphrey, he was Managing Director and Senior Research Analyst at Global Hunter Securities, an investment bank, from 2011 to 2012. Prior to Global Hunter Securities, he was Senior Healthcare Analyst at The Agave Group, LLC, a registered investment advisor, from 2008 to 2011. Prior to The Agave Group, he was an Executive Director and Senior Biotechnology Analyst at CIBC World Markets, an investment bank, from 2006 to 2008. Prior to CIBC, he was a research scientist in small molecule drug discovery at Amgen, a biotechnology company. Prior to Amgen, he was a research scientist at Microcide Pharmaceuticals, a biotechnology company. Dr. Lian holds an MBA in accounting and finance from Indiana University, an MS and Ph.D. in organic chemistry from The University of Michigan, and a BA in chemistry from Whitman College. - Brian Lian自2019年1月起担任董事。他是我们薪酬委员会的主席，我们审计委员会的成员和我们公司治理/提名委员会的成员。他目前是VikingTherapeutics，Inc.的总裁兼首席执行官和董事。Nasdaq:VKTX，生物制药公司，加入Viking之前，2012-2013，他是投资银行SunTrust Robinson Humphrey的董事总经理、高级研究分析师。在SunTrust Robinson Humphrey，他负责小型和中型生物技术公司的覆盖，重点是糖尿病、肿瘤学、传染病和神经学领域的公司。任职SunTrust Robinson Humphrey公司之前，他曾担任Global Hunter Securities公司（投资银行）的董事总经理兼高级研究分析师（2011年至2012年）。任职Global Hunter Securities公司之前，他曾担任Agave Group，LLC（注册投资顾问）的高级梦百合分析师（2008年至2011年）。任职Agave Group公司之前，他曾担任CIBC World Markets公司（投资银行）的执行董事兼高级生物技术分析师（2006年至2008年）。任职CIBC公司之前，他曾担任Amgen公司（生物技术公司）的小分子药物发现研究科学家。任职Amgen公司之前，他曾担任Microcide Pharmaceuticals公司（生物技术公司）的研究科学家。Lian博士拥有印第安纳大学（Indiana University）的会计和金融工商管理硕士学位，密歇根大学（University of Michigan）的有机化学硕士和博士学位，以及惠特曼学院（Whitman College）的化学学士学位。
- Brian Lian has been a director since January 2019. He is the Chair of our Compensation Committee, a member of our Audit Committee and a member of our Corporate Governance/Nominating Committee. He is currently President and Chief Executive Officer and a Director of Viking Therapeutics, Inc. Nasdaq: VKTX, a biopharmaceutical company.Prior to joining Viking, he was a Managing Director and Senior Research Analyst at SunTrust Robinson Humphrey, an investment bank, from 2012 to 2013. At SunTrust Robinson Humphrey, he was responsible for coverage of small and mid-cap biotechnology companies with an emphasis on companies in the diabetes, oncology, infectious disease and neurology spaces. Prior to SunTrust Robinson Humphrey, he was Managing Director and Senior Research Analyst at Global Hunter Securities, an investment bank, from 2011 to 2012. Prior to Global Hunter Securities, he was Senior Healthcare Analyst at The Agave Group, LLC, a registered investment advisor, from 2008 to 2011. Prior to The Agave Group, he was an Executive Director and Senior Biotechnology Analyst at CIBC World Markets, an investment bank, from 2006 to 2008. Prior to CIBC, he was a research scientist in small molecule drug discovery at Amgen, a biotechnology company. Prior to Amgen, he was a research scientist at Microcide Pharmaceuticals, a biotechnology company. Dr. Lian holds an MBA in accounting and finance from Indiana University, an MS and Ph.D. in organic chemistry from The University of Michigan, and a BA in chemistry from Whitman College.
高管简历
中英对照 | 中文 | 英文- Michael Morneau
Michael Morneau，2014年7月起担任首席财务官。他拥有20年以上会计和财务经验，在多家生物技术和会计行业上市和私人公司工作过。2009年到2014年在Viking工作之前，他是Trius Therapeutics, Inc（Cubist Pharmaceuticals, Inc.子公司，一家制药公司，2013年9月Cubist收购Trius）财务副总裁和首席财务官。加入Trius之前，2008年到2009年，他是Lilly Research Labs Finance at Eli Lilly and Company（一家制药公司）董事长。加入Eli Lilly之前，2006年到2008年，他是SGX Pharmaceuticals, Inc.（一家生物科技公司，被 Eli Lilly收购）财务和会计董事长。加入SGX之前，2004年到2006年，他是Momenta Pharmaceuticals, Inc.（一家生物科技公司）财务总监。他获得了New Hampshire College工商管理硕士学位和会计硕士学位和 the University of New Hampshire数学学士学位。
Michael Morneau has served as our Chief Financial Officer since May 2014. Mr. Morneau has over 25 years of accounting and financial experience at public and private companies in the biotechnology and accounting industries. Prior to Viking, from 2009 to 2014 he was VP of Finance and Chief Accounting Officer at Trius Therapeutics, Inc., a subsidiary of Cubist Pharmaceuticals, Inc., a pharmaceutical company, following Cubist’s acquisition of Trius in September 2013. Prior to Trius, from 2008 to 2009 he was Director of Lilly Research Labs Finance at Eli Lilly and Company, a pharmaceutical company. Prior to Eli Lilly, from 2006 to 2008 he was Director of Finance and Accounting at SGX Pharmaceuticals, Inc., a biotechnology company, which was acquired by Eli Lilly. Prior to SGX, from 2004 to 2006 he was Controller at Momenta Pharmaceuticals, Inc., a biotechnology company. Mr. Morneau earned his MBA and MA in accounting from New Hampshire College, and a BA in mathematics from the University of New Hampshire.- Michael Morneau，2014年7月起担任首席财务官。他拥有20年以上会计和财务经验，在多家生物技术和会计行业上市和私人公司工作过。2009年到2014年在Viking工作之前，他是Trius Therapeutics, Inc（Cubist Pharmaceuticals, Inc.子公司，一家制药公司，2013年9月Cubist收购Trius）财务副总裁和首席财务官。加入Trius之前，2008年到2009年，他是Lilly Research Labs Finance at Eli Lilly and Company（一家制药公司）董事长。加入Eli Lilly之前，2006年到2008年，他是SGX Pharmaceuticals, Inc.（一家生物科技公司，被 Eli Lilly收购）财务和会计董事长。加入SGX之前，2004年到2006年，他是Momenta Pharmaceuticals, Inc.（一家生物科技公司）财务总监。他获得了New Hampshire College工商管理硕士学位和会计硕士学位和 the University of New Hampshire数学学士学位。
- Michael Morneau has served as our Chief Financial Officer since May 2014. Mr. Morneau has over 25 years of accounting and financial experience at public and private companies in the biotechnology and accounting industries. Prior to Viking, from 2009 to 2014 he was VP of Finance and Chief Accounting Officer at Trius Therapeutics, Inc., a subsidiary of Cubist Pharmaceuticals, Inc., a pharmaceutical company, following Cubist’s acquisition of Trius in September 2013. Prior to Trius, from 2008 to 2009 he was Director of Lilly Research Labs Finance at Eli Lilly and Company, a pharmaceutical company. Prior to Eli Lilly, from 2006 to 2008 he was Director of Finance and Accounting at SGX Pharmaceuticals, Inc., a biotechnology company, which was acquired by Eli Lilly. Prior to SGX, from 2004 to 2006 he was Controller at Momenta Pharmaceuticals, Inc., a biotechnology company. Mr. Morneau earned his MBA and MA in accounting from New Hampshire College, and a BA in mathematics from the University of New Hampshire.
- Brian Lian
Brian Lian自2019年1月起担任董事。他是我们薪酬委员会的主席，我们审计委员会的成员和我们公司治理/提名委员会的成员。他目前是VikingTherapeutics，Inc.的总裁兼首席执行官和董事。Nasdaq:VKTX，生物制药公司，加入Viking之前，2012-2013，他是投资银行SunTrust Robinson Humphrey的董事总经理、高级研究分析师。在SunTrust Robinson Humphrey，他负责小型和中型生物技术公司的覆盖，重点是糖尿病、肿瘤学、传染病和神经学领域的公司。任职SunTrust Robinson Humphrey公司之前，他曾担任Global Hunter Securities公司（投资银行）的董事总经理兼高级研究分析师（2011年至2012年）。任职Global Hunter Securities公司之前，他曾担任Agave Group，LLC（注册投资顾问）的高级梦百合分析师（2008年至2011年）。任职Agave Group公司之前，他曾担任CIBC World Markets公司（投资银行）的执行董事兼高级生物技术分析师（2006年至2008年）。任职CIBC公司之前，他曾担任Amgen公司（生物技术公司）的小分子药物发现研究科学家。任职Amgen公司之前，他曾担任Microcide Pharmaceuticals公司（生物技术公司）的研究科学家。Lian博士拥有印第安纳大学（Indiana University）的会计和金融工商管理硕士学位，密歇根大学（University of Michigan）的有机化学硕士和博士学位，以及惠特曼学院（Whitman College）的化学学士学位。
Brian Lian has been a director since January 2019. He is the Chair of our Compensation Committee, a member of our Audit Committee and a member of our Corporate Governance/Nominating Committee. He is currently President and Chief Executive Officer and a Director of Viking Therapeutics, Inc. Nasdaq: VKTX, a biopharmaceutical company.Prior to joining Viking, he was a Managing Director and Senior Research Analyst at SunTrust Robinson Humphrey, an investment bank, from 2012 to 2013. At SunTrust Robinson Humphrey, he was responsible for coverage of small and mid-cap biotechnology companies with an emphasis on companies in the diabetes, oncology, infectious disease and neurology spaces. Prior to SunTrust Robinson Humphrey, he was Managing Director and Senior Research Analyst at Global Hunter Securities, an investment bank, from 2011 to 2012. Prior to Global Hunter Securities, he was Senior Healthcare Analyst at The Agave Group, LLC, a registered investment advisor, from 2008 to 2011. Prior to The Agave Group, he was an Executive Director and Senior Biotechnology Analyst at CIBC World Markets, an investment bank, from 2006 to 2008. Prior to CIBC, he was a research scientist in small molecule drug discovery at Amgen, a biotechnology company. Prior to Amgen, he was a research scientist at Microcide Pharmaceuticals, a biotechnology company. Dr. Lian holds an MBA in accounting and finance from Indiana University, an MS and Ph.D. in organic chemistry from The University of Michigan, and a BA in chemistry from Whitman College.- Brian Lian自2019年1月起担任董事。他是我们薪酬委员会的主席，我们审计委员会的成员和我们公司治理/提名委员会的成员。他目前是VikingTherapeutics，Inc.的总裁兼首席执行官和董事。Nasdaq:VKTX，生物制药公司，加入Viking之前，2012-2013，他是投资银行SunTrust Robinson Humphrey的董事总经理、高级研究分析师。在SunTrust Robinson Humphrey，他负责小型和中型生物技术公司的覆盖，重点是糖尿病、肿瘤学、传染病和神经学领域的公司。任职SunTrust Robinson Humphrey公司之前，他曾担任Global Hunter Securities公司（投资银行）的董事总经理兼高级研究分析师（2011年至2012年）。任职Global Hunter Securities公司之前，他曾担任Agave Group，LLC（注册投资顾问）的高级梦百合分析师（2008年至2011年）。任职Agave Group公司之前，他曾担任CIBC World Markets公司（投资银行）的执行董事兼高级生物技术分析师（2006年至2008年）。任职CIBC公司之前，他曾担任Amgen公司（生物技术公司）的小分子药物发现研究科学家。任职Amgen公司之前，他曾担任Microcide Pharmaceuticals公司（生物技术公司）的研究科学家。Lian博士拥有印第安纳大学（Indiana University）的会计和金融工商管理硕士学位，密歇根大学（University of Michigan）的有机化学硕士和博士学位，以及惠特曼学院（Whitman College）的化学学士学位。
- Brian Lian has been a director since January 2019. He is the Chair of our Compensation Committee, a member of our Audit Committee and a member of our Corporate Governance/Nominating Committee. He is currently President and Chief Executive Officer and a Director of Viking Therapeutics, Inc. Nasdaq: VKTX, a biopharmaceutical company.Prior to joining Viking, he was a Managing Director and Senior Research Analyst at SunTrust Robinson Humphrey, an investment bank, from 2012 to 2013. At SunTrust Robinson Humphrey, he was responsible for coverage of small and mid-cap biotechnology companies with an emphasis on companies in the diabetes, oncology, infectious disease and neurology spaces. Prior to SunTrust Robinson Humphrey, he was Managing Director and Senior Research Analyst at Global Hunter Securities, an investment bank, from 2011 to 2012. Prior to Global Hunter Securities, he was Senior Healthcare Analyst at The Agave Group, LLC, a registered investment advisor, from 2008 to 2011. Prior to The Agave Group, he was an Executive Director and Senior Biotechnology Analyst at CIBC World Markets, an investment bank, from 2006 to 2008. Prior to CIBC, he was a research scientist in small molecule drug discovery at Amgen, a biotechnology company. Prior to Amgen, he was a research scientist at Microcide Pharmaceuticals, a biotechnology company. Dr. Lian holds an MBA in accounting and finance from Indiana University, an MS and Ph.D. in organic chemistry from The University of Michigan, and a BA in chemistry from Whitman College.